The 340B drug discount program was created with a noble mission – to ensure that underserved, low-income and uninsured patients receive the medications they need at little to no cost. The goal was to ensure that vulnerable patients can better adhere to their prescribed medications and improve the healthcare of patients who may otherwise be unable to afford their medications.
Over the past three decades, the program has grown greatly, demonstrating weaknesses in its implementation and execution. These weaknesses fail to consistently serve patients in need and compromise the ability of providers outside the 340B program to continue offering essential care in the community. The 340B drug discount program would benefit from realigning the program’s mission by placing the patient first and by establishing greater transparency and accountability to ensure the program’s success. For more information on CSRO’s position on the 340B Drug Discount Program, read our Explanatory Statement and Policy Position.
The Coalition of State Rheumatology Organizations (CSRO) supports federal and state legislative reforms to the 340B program that do not exacerbate healthcare consolidation, improve transparency and oversight of the program and realign the program’s mission to better serve vulnerable patient populations. CSRO is also a member of the Alliance for Integrity & Reform of 340B and the Alliance to Save America’s 340B Program, which advocate for federal legislative reforms.
Visit our Legislative Map Tool to read about legislation in your state. You can send letters in support of pending legislation and find educational materials.
